Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 2/20 | 0.47 |
| ▸ | TTBK2 | Q6IQ55 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 7/20 | 0.37 |
| ▸ | JAK2 | O60674 | 6/20 | 0.37 |
| ▸ | JAK1 | P23458 | 6/20 | 0.37 |
| ▸ | TYK2 | P29597 | 6/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15154891 | 0.82 | KDR (0.47) | TTBK1TTBK2KDRTRPA1AXL | |
| SCHEMBL1469019 | 0.79 | TTBK1 (0.46) | TTBK1TTBK2KDRTRPA1AXL | |
| SCHEMBL21863372 | 0.77 | PRKCI (0.46) | TTBK1TTBK2KDRTRPA1AXL | |
| SCHEMBL1468910 | 0.76 | CCNK (0.43) | TTBK1TTBK2KDRTRPA1AXL | |
| SCHEMBL2986157 | 0.76 | CIT (0.50) | TTBK1TTBK2KDRAXLPRKCI | |
| SCHEMBL21849266 | 0.74 | AXL (0.44) | TTBK1TTBK2KDRTRPA1AXL | |
| SCHEMBL24311307 | 0.74 | KDR (0.40) | TTBK1TTBK2KDRTRPA1AXL | |
| SCHEMBL15155103 | 0.73 | PRKCI (0.62) | TTBK1TTBK2KDRTRPA1AXL | |
| SCHEMBL3721031 | 0.73 | HTR2C (0.48) | TTBK1TTBK2JAK3JAK2JAK1 | |
| SCHEMBL15155083 | 0.73 | KDR (0.39) | KDRTRPA1AXLPRKCINUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841304-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140221370-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-08-07 | — | — | US | disclosed |
| CN-101959887-B | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC | 2013-07-31 | — | — | CN | disclosed |
| EP-2242755-B1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-09-12 | — | — | EP | disclosed |
| CN-101959887-A | Pyrrolopyridine as kinase inhibitor | ARRAY BIOPHARMA INC | 2011-01-26 | — | — | CN | disclosed |
| US-20100324041-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2242755-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009089352-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221370-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, BUB1B | TTBK1 91/4885TTBK2 147/4885KDR 3002/4885 |
| US-20100324041-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, BUB1B | TTBK1 103/4885TTBK2 157/4885KDR 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.